BELGRADE, Serbia—Dapagliflozin (Farxiga; AstraZeneca) does not further improve quality of ... or impaired LVEF) to dapagliflozin 10 mg once daily or standard care, was the first trial to extend those ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

We compared the dapagliflozin 10 mg (n = 179) and saxagliptin 5 mg (n = 176 ... This analysis was supported by AstraZeneca. Editorial support was provided by Shelley Narula of in Science ...

Use of the AstraZeneca Dapagliflozin Patient Identification Resource (DAPA-id) to identify patients in your practice who may benefit from taking dapagliflozin. • Opportunities to improve your practice ...

DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

AstraZeneca manufactures Farxiga, one of the drugs selected in the first round of drug price negotiations under the Program. Farxiga (dapagliflozin) is used to treat diabetes, heart disease ...

Matthew Herper covers medical innovation — both its promise and its perils. A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap ...

Drugmakers said it could cost them $1 trillion over the next decade. A U.S. appeals court shut down AstraZeneca’s challenge to the U.S. government program that gives Medicare the power to ...

Most safety profiles were grade 1 and 2. Treatment with 80 mg once daily osimertinib achieved a median OS of 15.0 months and an objective response rate of 51.6%, alongside a disease control rate of 81 ...

With the new devices — the Whoop 5.0 and Whoop MG, short for medical grade — the company is looking to gather a wider audience and add to an array of gadgets pitched as smartwatch alternatives.

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing ...